BR112014011144A2 - tratamento de malignidades hematológicas com um anticorpo anti-cxcr4 - Google Patents

tratamento de malignidades hematológicas com um anticorpo anti-cxcr4

Info

Publication number
BR112014011144A2
BR112014011144A2 BR112014011144A BR112014011144A BR112014011144A2 BR 112014011144 A2 BR112014011144 A2 BR 112014011144A2 BR 112014011144 A BR112014011144 A BR 112014011144A BR 112014011144 A BR112014011144 A BR 112014011144A BR 112014011144 A2 BR112014011144 A2 BR 112014011144A2
Authority
BR
Brazil
Prior art keywords
antibody
cxcr4
treating
individual
disclosure
Prior art date
Application number
BR112014011144A
Other languages
English (en)
Portuguese (pt)
Inventor
Pan Chin
m cardarelli Josephine
R Kuhne Michelle
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of BR112014011144A2 publication Critical patent/BR112014011144A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR112014011144A 2011-11-09 2012-11-09 tratamento de malignidades hematológicas com um anticorpo anti-cxcr4 BR112014011144A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161557815P 2011-11-09 2011-11-09
US201161569113P 2011-12-09 2011-12-09
PCT/US2012/064395 WO2013071068A2 (en) 2011-11-09 2012-11-09 Treatment of hematologic malignancies with an anti-cxcr4 antibody

Publications (1)

Publication Number Publication Date
BR112014011144A2 true BR112014011144A2 (pt) 2017-05-16

Family

ID=47179025

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014011144A BR112014011144A2 (pt) 2011-11-09 2012-11-09 tratamento de malignidades hematológicas com um anticorpo anti-cxcr4

Country Status (24)

Country Link
US (2) US10428151B2 (cg-RX-API-DMAC7.html)
EP (1) EP2776032B1 (cg-RX-API-DMAC7.html)
JP (1) JP6541350B2 (cg-RX-API-DMAC7.html)
KR (1) KR102024957B1 (cg-RX-API-DMAC7.html)
CN (1) CN104039320B (cg-RX-API-DMAC7.html)
AU (1) AU2012335553B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014011144A2 (cg-RX-API-DMAC7.html)
CA (1) CA2855155A1 (cg-RX-API-DMAC7.html)
CY (1) CY1121331T1 (cg-RX-API-DMAC7.html)
DK (1) DK2776032T3 (cg-RX-API-DMAC7.html)
EA (1) EA026153B1 (cg-RX-API-DMAC7.html)
ES (1) ES2705001T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20182183T1 (cg-RX-API-DMAC7.html)
HU (1) HUE043001T2 (cg-RX-API-DMAC7.html)
IL (1) IL232517B (cg-RX-API-DMAC7.html)
LT (1) LT2776032T (cg-RX-API-DMAC7.html)
MX (1) MX357100B (cg-RX-API-DMAC7.html)
PL (1) PL2776032T3 (cg-RX-API-DMAC7.html)
PT (1) PT2776032T (cg-RX-API-DMAC7.html)
RS (1) RS58102B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201401386XA (cg-RX-API-DMAC7.html)
SI (1) SI2776032T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201900026T1 (cg-RX-API-DMAC7.html)
WO (1) WO2013071068A2 (cg-RX-API-DMAC7.html)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2066351T1 (sl) * 2006-10-02 2016-02-29 E.R. Squibb & Sons, L.L.C. Humana protitelesa, ki vežejo cxcr4 in njihova uporaba
ES2624981T3 (es) 2011-07-01 2017-07-18 Dana-Farber Cancer Institute, Inc. Descubrimiento de una mutación somática en el gen MYD88 en linfoma linfoplasmocitario
EP3030322A2 (en) * 2013-08-05 2016-06-15 Cambridge Enterprise Limited Inhibition of cxcr4 signaling in cancer immunotherapy
CA2922398C (en) 2013-09-12 2023-08-29 Dana-Farber Cancer Institute, Inc. Methods for evaluating and treating waldenstrom's macroglobulinemia
EP3066129B1 (en) * 2013-11-06 2019-06-19 Bristol-Myers Squibb Company Treatment of c1013g/cxcr4-associated waldenström's macroglobulinemia with an anti-cxcr4 antibody
CA2930326C (en) 2013-12-06 2022-09-06 Dana-Farber Cancer Institute, Inc. Methods to distinguish waldenstrom's macroglobulinemia from igm monoclonal gammopathy of undetermined significance
USRE50030E1 (en) 2013-12-13 2024-07-02 Dana-Farber Cancer Institute, Inc. Methods to treat lymphoplasmacytic lymphoma
EP3572425A1 (en) * 2013-12-17 2019-11-27 AIMM Therapeutics B.V. Means and methods for counteracting myeloproliferative or lymphoproliferative disorders
CN106573976B (zh) * 2014-02-06 2020-05-05 耶达研究及发展有限公司 抗cd84抗体、包含所述抗体的组合物及其用途
JP2017508005A (ja) * 2014-02-19 2017-03-23 マイクロコンスタンツ チャイナ インク ケモカイン受容体アンタゴニストおよびその併用療法
DK3242685T3 (da) * 2015-01-09 2022-07-25 Adalta Ltd Cxcr4-bindende molekyler
HRP20201334T1 (hr) 2015-04-17 2020-11-27 Bristol-Myers Squibb Company Kompozicije koje sadrže kombinaciju ipilimumaba i nivolumaba
US20180179282A1 (en) 2015-06-12 2018-06-28 Bristol-Myers Squibb Company Treatment of cancer by combined blockade of the pd-1 and cxcr4 signaling pathways
MX2017016844A (es) 2015-07-16 2018-08-15 Biokine Therapeutics Ltd Composiciones y procedimientos para tratar cancer.
US11219694B2 (en) 2015-09-24 2022-01-11 The University Of North Carolina At Chapel Hill Methods and compositions for reducing metastases
WO2017083440A1 (en) * 2015-11-09 2017-05-18 The General Hospital Corporation D.B.A Massachusetts General Hospital Unit dose formulations for use as an anti-fugetactic agent
CA3014530A1 (en) * 2016-02-23 2017-08-31 Biolinerx Ltd. Methods of treating acute myeloid leukemia
JP2019518006A (ja) 2016-04-29 2019-06-27 デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド Myd88変異型疾患における治療標的としてのhck
HRP20220237T1 (hr) 2016-05-20 2022-04-29 Biohaven Therapeutics Ltd. Primjena riluzola, prolijekova riluzola ili analoga riluzola sa imunoterapijama za liječenje raka
WO2017216368A1 (en) * 2016-06-16 2017-12-21 Centre National De La Recherche Scientifique Compounds useful for decreasing interferon level
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
CA3052070A1 (en) * 2017-01-31 2018-08-09 Msm Protein Technologies Inc. Anti-cxcr4 antibodies
WO2018156609A1 (en) * 2017-02-21 2018-08-30 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
EP3601355A1 (en) 2017-03-31 2020-02-05 Bristol-Myers Squibb Company Methods of treating tumor
EP3694884A1 (en) 2017-10-15 2020-08-19 Bristol-Myers Squibb Company Methods of treating tumor
US20210162009A1 (en) * 2017-12-08 2021-06-03 The Medical College Of Wisconsin, Inc. Chemokine variants as immune stimulants
CN112513079A (zh) * 2018-03-13 2021-03-16 拉巴斯大学医院生物医学研究基金会 用于癌症免疫疗法的联合激活和扩增的自然杀伤细胞的抗cxcr4抗体
JP7351845B2 (ja) 2018-03-23 2023-09-27 ブリストル-マイヤーズ スクイブ カンパニー Micaおよび/またはmicbに対する抗体ならびにそれらの使用
KR102825164B1 (ko) 2018-03-27 2025-06-26 브리스톨-마이어스 스큅 컴퍼니 자외선 신호를 사용한 단백질 농도의 실시간 모니터링
EP3774911A1 (en) 2018-03-30 2021-02-17 Bristol-Myers Squibb Company Methods of treating tumor
WO2020172658A1 (en) 2019-02-24 2020-08-27 Bristol-Myers Squibb Company Methods of isolating a protein
KR20220012292A (ko) 2019-05-23 2022-02-03 브리스톨-마이어스 스큅 컴퍼니 세포 배양 배지를 모니터링하는 방법
CN114746095B (zh) 2019-10-08 2025-01-24 达纳-法伯癌症研究所有限公司 Hck作为myd88突变疾病的治疗靶点
US12679842B2 (en) 2019-10-08 2026-07-14 Dana-Farber Cancer Institute, Inc. HCK as a therapeutic target in MYD88 mutated diseases
JP2023544410A (ja) 2020-10-05 2023-10-23 ブリストル-マイヤーズ スクイブ カンパニー タンパク質を濃縮するための方法
PT4267105T (pt) 2020-12-28 2025-04-30 Bristol Myers Squibb Co Composições de anticorpos e métodos de utilização das mesmas
AU2021416156A1 (en) 2020-12-28 2023-06-22 Bristol-Myers Squibb Company Methods of treating tumors
JP2024514530A (ja) 2021-04-02 2024-04-02 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 切断型cdcp1に対する抗体およびその使用
KR20240156411A (ko) 2022-03-09 2024-10-29 브리스톨-마이어스 스큅 컴퍼니 치료 단백질의 일시적 발현
US20240294651A1 (en) * 2023-01-30 2024-09-05 Kymab Limited Antibodies
CN122459678A (zh) 2023-12-29 2026-07-24 百时美施贵宝公司 KRAS抑制剂与Treg耗竭剂的组合疗法
CN119119196B (zh) * 2024-08-01 2025-09-09 青岛大学 一种基于Motixafortide-喜树碱缀合物及其制备方法和应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
JP3367581B2 (ja) 1993-10-14 2003-01-14 小野薬品工業株式会社 新規なポリペプチド、その製造方法、そのポリペプチドをコードするdna、そのdnaからなるベクター、そのベクターで形質転換された宿主細胞
US6794132B2 (en) 1999-10-02 2004-09-21 Biosite, Inc. Human antibodies
DE60131456T2 (de) 2000-11-30 2008-07-10 Medarex, Inc., Milpitas Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
ES2374526T3 (es) 2003-09-04 2012-02-17 Medarex, Inc. Vector de expresión.
US8329178B2 (en) 2005-02-18 2012-12-11 Dana-Farber Cancer Institute, Inc. Antibodies against CXCR4 and methods of use thereof
US8569280B2 (en) * 2005-04-25 2013-10-29 Immune Disease Institute Methods for the treatment of multiple myeloma
HUE028055T2 (en) 2006-02-28 2016-11-28 Pharma Mar Sa Improved treatment of myeloma multiplex
SI2066351T1 (sl) * 2006-10-02 2016-02-29 E.R. Squibb & Sons, L.L.C. Humana protitelesa, ki vežejo cxcr4 in njihova uporaba
FR2915102B1 (fr) 2007-04-23 2014-05-16 Pf Medicament Utilisation d'un anticorps anti-cxcr4 pour le traitement du cancer
EP2297206A1 (en) 2008-05-14 2011-03-23 Eli Lilly And Company Anti-cxcr4 antibodies
WO2010043650A2 (en) 2008-10-14 2010-04-22 Ablynx Nv Amino acid sequences directed against cellular receptors for viruses and bacteria
JP5709766B2 (ja) * 2009-03-12 2015-04-30 ジェネンテック, インコーポレイテッド 造血器腫瘍の治療のためのホスホイノシチド3キナーゼ阻害剤化合物と化学療法剤の併用
RU2636614C2 (ru) * 2009-05-19 2017-11-24 Вивия Байотек С.Л. Способы персонализированного медицинского тестирования ex vivo на гематологические новообразования
EP2605797A2 (en) 2010-08-20 2013-06-26 Cerulean Pharma Inc. Therapeutic peptide-polymer conjugates, particles, compositions, and related methods

Also Published As

Publication number Publication date
HUE043001T2 (hu) 2019-07-29
PT2776032T (pt) 2019-01-21
HRP20182183T1 (hr) 2019-02-22
KR20140093945A (ko) 2014-07-29
MX357100B (es) 2018-06-26
CN104039320A (zh) 2014-09-10
EP2776032A2 (en) 2014-09-17
WO2013071068A2 (en) 2013-05-16
ES2705001T3 (es) 2019-03-21
SI2776032T1 (sl) 2018-12-31
EP2776032B1 (en) 2018-10-17
SMT201900026T1 (it) 2019-05-10
CA2855155A1 (en) 2013-05-16
LT2776032T (lt) 2018-12-10
JP6541350B2 (ja) 2019-07-10
WO2013071068A3 (en) 2013-07-18
IL232517B (en) 2018-05-31
EA026153B1 (ru) 2017-03-31
CN104039320B (zh) 2019-10-15
RS58102B1 (sr) 2019-02-28
AU2012335553A1 (en) 2014-07-03
JP2014533279A (ja) 2014-12-11
US10428151B2 (en) 2019-10-01
PL2776032T3 (pl) 2019-03-29
KR102024957B1 (ko) 2019-09-24
DK2776032T3 (en) 2019-02-04
AU2012335553B2 (en) 2017-09-21
EA201490957A1 (ru) 2014-08-29
US20140322208A1 (en) 2014-10-30
MX2014005267A (es) 2014-07-28
SG11201401386XA (en) 2014-10-30
CY1121331T1 (el) 2020-05-29
US20200231683A1 (en) 2020-07-23
IL232517A0 (en) 2014-06-30

Similar Documents

Publication Publication Date Title
MX357100B (es) Tratamiento de neoplasias hematologicas con un anticuerpo anti-cxcr4.
BR102012006063A8 (pt) Inibidor de met para uso no tratamento de um paciente sofrendo de um tumor, e, sequência de nucleotídeo
UA114712C2 (uk) Моноклональне антитіло, яке імуноспецифічно зв'язується з людським psgl-1, та його застосування
BR112013029330A2 (pt) "uso de anticorpo imunoconjugado maitansinoide anti-cd19 na preparação de composição para tratamento de sintomas de doenças de célula-b, imunoconjugado maitansinoide anti-cd19 e artigo de fabricação"
MX2018010331A (es) Agentes de ligacion al factor de crecimiento endotelial vascular/ligando 4 similar a delta (vegf/dll4) y usos de los mismos.
MY179577A (en) Anti-cd3 antibodies, bispecific antigen-binding molecules that bind cd3 and cd20, and uses thereof
NZ737726A (en) Multispecific antigen-binding molecules and uses thereof
MX2011013424A (es) Metodo de tratamiento del cancer con antagonista dll4 y agente quimioterapeutico.
PH12013500826A1 (en) Means and methods for treating dlbcl
BR112021011684A2 (pt) Terapia combinada com cd70 e venetoclax, um inibidor de bcl-2, para o tratamento da leucemia mieloide aguda
BR112014029099A2 (pt) anticorpos anti-egfr e seu uso para inibir ou atenuar crescimento de tumor, bem como composição farmacêutica que o compreende
BR112014008804A2 (pt) suportes derivados de tn3 específicos para cd40l e métodos de uso dos mesmos
BR112014007382A2 (pt) anticorpos anti-erbb3 e seus usos
NZ601580A (en) Therapeutic methods using anti-cd200 antibodies
PH12015500084A1 (en) Rspo3 binding agents and uses thereof
MX2023014069A (es) Composiciones y métodos para el tratamiento del cáncer de próstata.
EP4434540A3 (en) Humanized anti-il-1r3 antibodies
BR112014016723A2 (pt) método para o tratamento de câncer de mama
BR112013033544A2 (pt) dosagem e administração de anticorpos anti-erbb3 em combinação com paclitaxel para tratamento de cânceres ginecológicos
BR112015031950A2 (pt) métodos para tratamento de câncer de ovário
MX2022001403A (es) Metodos de administracion de anticuerpos anti-siglec-8 y corticosteroides.
BR112022022980A2 (pt) Uso de inibidores de fator d de complemento sozinhos ou em combinação com anticorpos anti-c5 para tratamento de hemoglobinúria paroxística noturna
MX2022001411A (es) Metodos para tratar o prevenir canceres que implican la administracion de agentes receptores anti-ccr5.
EA201001731A1 (ru) Применение радиоактивно меченой молекулы, которая специфически связывается с ed-b фибронектином, в способе лечения лимфомы ходжкина
NZ776617A (en) Methods of conditioning patients for t cell therapy

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements
B350 Update of information on the portal [chapter 15.35 patent gazette]